Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

1.89

Margin Of Safety %

30

Put/Call OI Ratio

0.96

EPS Next Q Diff

-0.11

EPS Last/This Y

5.16

EPS This/Next Y

-0.27

Price

44.23

Target Price

53.37

Analyst Recom

2.61

Performance Q

-10.84

Relative Volume

1.29

Beta

0.37

Ticker: BMY




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-07BMY46.490.941.82578176
2025-07-08BMY47.040.970.76591187
2025-07-09BMY47.650.971.12593825
2025-07-10BMY48.490.961.05599045
2025-07-11BMY46.850.970.84606910
2025-07-14BMY47.340.981.20604318
2025-07-15BMY46.41.010.77621535
2025-07-16BMY47.190.990.36636259
2025-07-17BMY48.080.990.49638570
2025-07-18BMY47.380.990.75657562
2025-07-21BMY46.720.970.37575814
2025-07-22BMY48.030.940.19585871
2025-07-23BMY490.890.47609010
2025-07-24BMY48.980.901.60621097
2025-07-25BMY48.460.903.65624892
2025-07-28BMY47.510.981.41634739
2025-07-29BMY46.870.990.94642913
2025-07-30BMY46.010.981.31653927
2025-07-31BMY43.340.991.49680590
2025-08-01BMY44.220.960.42698087
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-07BMY46.49-22.18776.36.76
2025-07-08BMY47.04-22.19027.86.76
2025-07-09BMY47.66-22.18885.76.76
2025-07-10BMY48.52-22.18944.56.76
2025-07-11BMY46.86-22.18527.36.76
2025-07-14BMY47.35-22.18852.96.76
2025-07-15BMY46.43-22.18498.66.76
2025-07-16BMY47.20-22.17397.36.76
2025-07-17BMY48.06-22.17422.96.76
2025-07-18BMY47.38-22.17063.26.76
2025-07-21BMY46.72-22.17070.76.76
2025-07-22BMY48.03-22.17528.96.76
2025-07-23BMY48.98-22.17436.46.76
2025-07-24BMY48.94-44.07208.86.42
2025-07-25BMY48.43-44.07103.26.42
2025-07-28BMY47.42-45.46989.36.34
2025-07-29BMY46.86-45.47068.76.34
2025-07-30BMY45.98-45.47013.96.34
2025-07-31BMY43.31-46.86591.36.31
2025-08-01BMY44.23-46.87446.76.31
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-07BMY0.392.691.65
2025-07-08BMY0.392.691.65
2025-07-09BMY0.392.691.65
2025-07-10BMY0.492.691.65
2025-07-11BMY0.492.691.94
2025-07-14BMY0.493.031.94
2025-07-15BMY0.493.031.94
2025-07-16BMY0.493.031.94
2025-07-17BMY0.493.031.94
2025-07-18BMY0.493.031.94
2025-07-21BMY0.492.951.94
2025-07-22BMY0.492.951.94
2025-07-23BMY0.492.951.94
2025-07-24BMY0.492.951.94
2025-07-25BMY0.492.951.89
2025-07-28BMY0.492.331.89
2025-07-29BMY0.492.331.89
2025-07-30BMY0.492.331.89
2025-07-31BMY0.492.331.89
2025-08-01BMY0.492.331.89
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

1.8

Avg. EPS Est. Current Quarter

1.61

Avg. EPS Est. Next Quarter

1.69

Insider Transactions

0.49

Institutional Transactions

2.33

Beta

0.37

Average Sales Estimate Current Quarter

11316

Average Sales Estimate Next Quarter

11645

Fair Value

57.35

Quality Score

82

Growth Score

44

Sentiment Score

11

Actual DrawDown %

45.7

Max Drawdown 5-Year %

-47.7

Target Price

53.37

P/E

17.85

Forward P/E

7.35

PEG

0.25

P/S

1.89

P/B

5.16

P/Free Cash Flow

6.17

EPS

2.48

Average EPS Est. Cur. Y​

6.31

EPS Next Y. (Est.)

6.05

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

10.58

Relative Volume

1.29

Return on Equity vs Sector %

7.4

Return on Equity vs Industry %

-0.8

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.45

EBIT Estimation

7446.7
Bristol-Myers Squibb Company
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 34100
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
stock quote shares BMY – Bristol-Myers Squibb Company Stock Price stock today
news today BMY – Bristol-Myers Squibb Company stock forecast ,stock prediction 2023 2024 2025
marketwatch BMY – Bristol-Myers Squibb Company yahoo finance google finance
stock history BMY – Bristol-Myers Squibb Company invest stock market
stock prices BMY premarket after hours
ticker BMY fair value insiders trading